

Since December 2009, SSRI has been approved by Innovation Australia as a Research Service Provider (RSP) capable of conducting R & D on behalf of others in the following categories of science:

2301	Mathematics	2499	Other Physical Sciences
2701	Biochemistry and Cell Biology	2708	Biotechnology
2799	Other Biological Sciences	2999	Other Engineering and Technology
3202	Immunology	3205	Pharmacology and Pharmaceutical Sciences

Engaging SSRI to undertake your R & D program allows your company to have access to the Institute's extensive expertise in antibody development, single cell analysis and manipulation, establishment and characterisation of novel human cell lines, adaptation to serum free media and initial cell culture scale up. It also allows access to SSRI's in-house built infrastructure including a unique cell bank of some 30 novel human cell lines to do your assays and testing.

Up to \$100M in R&D contractual expenditure with SSRI is eligible for the AusIndustry R&D Tax Incentive in the year of income with a normal annual expenditure threshold of \$20,000 being waived. Companies with annual turnover of less than \$20M are eligible to claim a refundable tax offset of 45% of their R&D expenditure in the income year. Other companies are eligible to claim a non-refundable tax offset of 40%.

SSRI's RSP Policy establishes a uniform set of guidelines for the development and administration of all externally funded research and R & D contracts as well as the costing of contract services and overhead cost recovery. You can view the policy by clicking on the link below.

[SSRI Contract Research Policy](#)

If you are an industry representative looking into working together with researchers at SSRI, please contact:

Dr. Galina Kaseko

+61 2 9209 4117

enquiries@ssri.org.au